Back to Search

New Combination Therapy for Extensive-Stage Small Cell Lung Cancer

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Recruiting Phase 3 Interventional Study
Extensive-Stage Small Cell Lung Cancer
More trials: Cancer clinical trials· Cancer trials in Alabama
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
530 (estimated)
Sponsor
Bristol-Myers Squibb · Industry
Who this trial is looking for

This trial is looking for people with extensive-stage small cell lung cancer. Participants will receive one of two different treatment combinations and will be monitored for their health and tumor response.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with extensive-stage small cell lung cancer.
  • I am healthy enough to perform my normal daily activities.
  • I have at least one tumor that can be measured using imaging tests.

You may not be able to join if

  • I have already received certain treatments for extensive-stage small cell lung cancer.
  • I have small cell lung cancer that has spread to my brain and is causing symptoms.
  • I have certain lung diseases or heart diseases.
  • I have infections or autoimmune diseases.
  • I have other types of cancer.
  • I have a condition called peripheral sensory neuropathy.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria * Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). * Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale. * Participants must have at least one tumor that can be measured…
Contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

855-907-3286

Clinical.Trials@bms.com

CONTACT

First line of the email MUST contain NCT # and Site #.

CONTACT

NCT ID: NCT06646276 Source: ClinicalTrials.gov